SCHEMBL19783211

SCHEMBL19783211

CC(C)(O)CCOc1cc(N)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.41
NUDT1 P36639 1/20 0.36
PIM1 P11309 1/20 0.36
LOX P28300 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
VDR P11473 2/20 0.34
MAPT P10636 2/20 0.34
TTBK1 Q5TCY1 1/20 0.34
GSK3B P49841 1/20 0.34
CYP2C9 P11712 1/20 0.33
ACVR2A P27037 1/20 0.33
TGFBR2 P37173 1/20 0.33
KCNH2 Q12809 1/20 0.33
LTB4R Q15722 2/20 0.33
LNPEP Q9UIQ6 1/20 0.33
ASIC3 Q9UHC3 1/20 0.33
AR P10275 1/20 0.32
PDE2A O00408 1/20 0.31
PDE10A Q9Y233 1/20 0.31
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189946 0.83 NUDT1 (0.45) NUDT1LOXLOXL2ACVR2ATGFBR2
SCHEMBL21379706 0.83 NUDT1 (0.45) NUDT1LOXLOXL2ACVR2ATGFBR2
SCHEMBL21395335 0.82 CYP2D6 (0.41) CYP2D6PIM1LOXLOXL2VDR
SCHEMBL18034671 0.81 ACVR2A (0.36) CYP2D6PIM1CYP2C9ACVR2ATGFBR2
SCHEMBL15464568 0.80 ADRB2 (0.42) CYP2D6PIM1VDRKCNH2AR
SCHEMBL23462840 0.79 ASIC3 (0.40) LOXLOXL2MAPTASIC3KDM4E
SCHEMBL28940925 0.78 CYP2D6 (0.46) CYP2D6PIM1LOXLOXL2MAPT
SCHEMBL2144434 0.77 LOXL2 (0.43) PIM1LOXLOXL2MAPTASIC3
SCHEMBL3340745 0.77 MAPT (0.50) LOXLOXL2MAPTASIC3MCHR1
SCHEMBL28292590 0.76 TSHR (0.46) CYP2D6PIM1MCHR1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP2D6 117/4885NUDT1 899/4885PIM1 4184/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP2D6 154/4885NUDT1 1005/4885PIM1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.